453. Tumorigenic Potential in Clones Derived from Rat Bone Marrow Cells

Abstract

Alongside the clinical and manufacturing developments essential for treating the first patient enrolled for the trial, the RegenVOX team have thus given careful consideration to a number of aspects of business modelling, in order to product accurate data to use in planning how to deliver the product within a clinical setting. Economic modelling performed to date and planned for the future is described here, along with other aspects of translational and business model development. Further work on exploring the potential market for a RegenVOX technology, as well as understanding patient costs and implications for product uptake and delivery will be discussed, as well as additional considerations for onward commercialisation and translation into routine healthcare.